Gain insights into Amneal Pharmaceuticals' Q2 2025 success, with strong growth, upgraded guidance, and promising launches like CREXONT and Brekiya.

But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt. So, the natural question for Metsera (NASDAQ:MTSR) shareholders is whether they should be ...

For those venture-backed companies that have made their public-market debuts this year, the reception has been exceptionally ...

VESPER-1 and interim VESPER-3 data release expected in September 2025; Phase 3 initiation on track for late 2025 MET-233i (once-monthly amylin analog) delivered ...

Investing.com -- Metsera , Inc. (NASDAQ: MTSR ), a clinical-stage biopharmaceutical company focused on obesity and metabolic diseases, reported a wider-than-expected second quarter loss on Monday, ...

Fashion Expert Melissa Garcia Teams with Gap to Discuss This Year’s Must-Have Styles and Trends ...

VESPER-1 and interim VESPER-3 data release expected in September 2025; Phase 3 initiation on track for late 2025 MET-233i (once-monthly amylin analog) delivered class-leading Phase 1 results including ...

Shares of ATAI Life Sciences NV ATAI -11.8% + Free Alerts fell sharply in pre-market trading after the company announced the ...

Dose escalation continues for Vir Biotechnology’s dual-masked TCEs VIR-5818 (targeting a variety of HER2-expressing solid tumors) and VIR-5500 (targeting PSMA in metastatic castration-resistant ...

AI-guided, synthetic lethal therapy achieves complete metabolic response after just two cycles in patient who failed three prior state-of-the-art treatment regimens. Complete response in an aggressive ...

When InvestingPro’s Fair Value models identified Metsera Inc. (NASDAQ:MTSR) as significantly undervalued on April 1, 2025, the healthcare company’s stock was trading at $24.51. Just three and a half ...

Metsera, a healthcare company focused on developing innovative treatments for obesity and metabolic disorders, had been flying under the radar despite its promising pipeline. When InvestingPro’s ...